#protease inhibitor

Research on the links between tenofovir and other antiretrovirals, SARS-CoV-2 infection and COVID severity has produced mixed results.

Writing for The Wall Street Journal in 1996, Sanford detailed how a new class of HIV meds turned his health around.

HIV treatment has greatly improved over the past 36 years.

Paxlovid dramatically reduced the risk of severe illness and death, but it must be started soon after developing symptoms.

Compared with efavirenz-based regimens, dolutegravir-containing ones resulted in fewer switches and better viral control.

Resistance to four HIV drug classes is tied to high risk of disease and death.

Two-drug antiretroviral regimens suppress viral load, but three-drug combos may offer additional benefits.

Researchers at George Washington University take a look.

This from a small study of people who switched from a boosted protease inhibitor to Isentress (raltegravir) or Tivicay (dolutegravir).

Protease inhibitors, including those used for hep C, and various other drugs may cause drug-drug interactions with statins.

Among those taking Epivir, taking two antiretrovirals instead of three was tied to fewer people stopping because of side effects.

A recent analysis of Europeans taking boosted protease inhibitors for HIV treatment found this pair prompted the best long-term response.

In a small study, the drop in seminal viral load in men who started treatment with PIs lagged behind that of men going on other HIV meds.